Adherence in allergen immunotherapy: Current situation and future implications.

Allergologie Select Pub Date : 2022-11-21 eCollection Date: 2022-01-01 DOI:10.5414/ALX02318E
Francesca Gehrt, Qingqing Xu, Ilaria Baiardini, Giorgio Walter Canonica, Oliver Pfaar
{"title":"Adherence in allergen immunotherapy: Current situation and future implications.","authors":"Francesca Gehrt, Qingqing Xu, Ilaria Baiardini, Giorgio Walter Canonica, Oliver Pfaar","doi":"10.5414/ALX02318E","DOIUrl":null,"url":null,"abstract":"<p><p>Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy. However clinical trials as well as real-life studies revealed poor treatment adherence. This article is intended to provide an overview of the current literature of the last 10 years, to outline reasons for poor treatment adherence in AIT and to provide possible solutions for improving adherence.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":" ","pages":"276-284"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707370/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie Select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02318E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy. However clinical trials as well as real-life studies revealed poor treatment adherence. This article is intended to provide an overview of the current literature of the last 10 years, to outline reasons for poor treatment adherence in AIT and to provide possible solutions for improving adherence.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
过敏原免疫疗法的依从性:当前形势与未来影响。
过敏原免疫疗法(AIT)是过敏症中唯一能改变病情的治疗方法。然而,临床试验和现实生活中的研究表明,治疗依从性很差。本文旨在概述过去 10 年的最新文献,概述过敏原免疫疗法治疗依从性差的原因,并提供改善依从性的可能解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Vegan diets from an allergy point of view - Position paper of the DGAKI working group on food allergy. Clinical endpoints in allergen immunotherapy: State of the art 2022. Allergic asthma: An indication for allergen immunotherapy. Allergen challenge tests in allergen immunotherapy: State of the art. Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1